MobiHealthNews

Dexcom CEO tells investors not to fear new competition from Abbott's Freestyle Libre

Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
The Motley Fool

Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?

Abbott and DexCom depend heavily on continuous glucose monitoring (CGM) device sales. Vertex is developing therapies that could cure type 1 diabetes. If Vertex is successful, the CGM market could be ...
Seeking Alpha

DexCom: Tremendous Growth Prospects

DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...
MD&M East

FDA Clears Dexcom’s 15-Day CGM System for Adult Diabetes Management

Dexcom has won a nod from FDA for the G7 15-Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes. With this clearance, the San Diego, CA-based company continues to ...